Pomerantz LLP Investigates Unicycive Therapeutics Securities Fraud Claims.

Pomerantz LLP is investigating claims of securities fraud against Unicycive Therapeutics. The investigation concerns whether the company and its officers have engaged in unlawful business practices. The FDA issued a Complete Response Letter for the company's New Drug Application for OLC to treat hyperphosphatemia in patients with chronic kidney disease. Investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

New York, July 2, 2025 - Pomerantz LLP, a leading law firm specializing in corporate, securities, and antitrust class litigation, has announced an investigation into claims on behalf of investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The investigation focuses on whether the company and its officers have engaged in unlawful business practices, including potential securities fraud.

The investigation stems from a recent press release issued by Unicycive on June 30, 2025. The company announced that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for OLC, a drug intended to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The CRL cited deficiencies at a third-party manufacturing vendor, which led to a significant drop in Unicycive's stock price, falling by $2.03 per share or 29.85%, to close at $4.77 per share on the same day.

Investors are advised to contact Danielle Peyton at dpeyton@pomlaw.com or 646-581-9980, ext. 7980, for more information about joining the class action [1][2].

Unicycive's stock price decline underscores the market's reaction to the regulatory setback. The company's management team has indicated that they are working to resolve the issues identified in the CRL and are exploring alternative manufacturing vendors to support the resolution of the Clinical Manufacturing and Controls (CMC) issues. The company's pipeline includes OLC for the treatment of hyperphosphatemia and UN-494 for acute kidney injury, both of which are in various stages of development [3].

Pomerantz LLP has a history of representing investors in securities fraud cases and has recovered numerous multimillion-dollar damages awards on behalf of class members. The firm is well-known for its expertise in securities class actions and continues to fight for the rights of victims of corporate misconduct [1][2].

References:
[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-unicycive-therapeutics-inc---uncy-302501956.html
[2] https://www.marketscreener.com/quote/stock/UNICYCIVE-THERAPEUTICS-IN-123776316/news/Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Unicycive-Therapeutics-Inc-UNCY-50495860/
[3] https://www.marketscreener.com/quote/stock/UNICYCIVE-THERAPEUTICS-IN-123776316/news/Unicycive-Therapeutics-July-2025-Corporate-Presentation-50463208/